(-11) 164L

EV 063563250 ರS

April 12, 2002

Date of Deposit

USPS Express Mail Label Number I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1 10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

√Nancy Foster 2 2002

PATENT Customer No. 22,852

Attorney Docket No. 6843.0028-02000

TED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tsutomu ARAKAWA et al.

Group Art Unit: 1642

Serial No.: 09/994,068

Examiner: Not Yet Assigned

Filed: November 27, 2001

ANTIBODY-INDUCED **APOPTOSIS**

RECEIVED
APR 1 8 2002

Assistant Commissioner for Patents Washington, DC 20231

TECH CENTER 1600 2900

Sir:

For:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. To the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were previously submitted or were cited by the Examiner in Application Serial No. 09/046,785, filed March 23, 1998, or in Application Serial No. 08/568,072, filed December 5, 1995, now U.S. Patent No. 5,783,186. Applicants rely upon those two applications for the benefits provided under 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed documents

LAW OFF CES -Finnegan, Henderson, FARABOW, GARRETT, & DUNNER, L.E.P. 1300 I STREET, N. W. WASHINGTON, DC 20005 202 408 4000

and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute prior art under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: April 12, 2002

Rebecca B. Scarr

Reg. No. 47,057

EAW OFFICES

FINNEGAN, HENDERSON,
EARABOW, GARRETT,
& DUNNER, L. L.D.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202 408 4000

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	6843.0028-02000	OIPE	Appln. No.	09/994,068	
Applicant	Tsutomu ARAKAW	et al.			
Filing Date	November 27, 200	א מממכיר בעשמ	Group:	1642	
		Car all			

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	4,676,980	06/1987	Segal et al.			
	4,954,617	09/1990	Fanger et al.			
	5,489,525	02/1996	Pastan			OEN/ED
						RECEIVED
						APR 1 8 2002
						TECH CENTER 1600

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
,	WO 94 00136	01/1994				
	WO 96 07321	03/1996				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Arakawa et al., <i>Arch. Biochem. Biophs.</i> , 308: 267-273 (1994).
· · · · · · · · · · · · · · · · · · ·	Bargmann et al., The Oncogene Handbook, pp. 107-119 (1988).
	Berchuck et al., Cancer Res., 50: 4087-4091 (1990).
	Campos-Gonzalez et al., Growth Factors, 4 (4): 305-316 (1991)
	Curiel, <i>Gene Therapy</i> , 2: 20 (1995).
	Coussens et al. Science 230: 1132-1139 (1985).
	Deshane et al., <i>Gynecol. Oncol.</i> 59: 8-14 (1995).
	Deshane et al., Journal of Investigative Medicine 32: 328A (1995).
	Drevin et al., <i>Oncogene</i> 2: 387-394 (1988).
	Falls et al., Cell 72: 801-815 (1993).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	6843.0028-02000 OFF Appln. No. 09/994,068 RECEIVED					
Applicant	Tsutomu ARAKAWA et al.					
Filing Date	November 27, 2001 Group: 1642 APR 1 8 2002					
	TECH CENTER 1600/29					
	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
	Fendly et al., Cancer Res., 50: 1550-1558 (1990).					
	Fukushinge et al., <i>Mol. Cell Biol.</i> , 6: 955-958 (1986). Grim et al., <i>Cancer Gene Therapy</i> , 1: 333-334 (1994).					
	Hanwerth et al., <i>Br. J. Cancer</i> , 68: 1140-1145 (1993).					
	Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988).					
	Holmes et al., Science, 256: 1205-1210 (1992).					
	Hudziak et al., <i>Mol. Cell Biol.</i> , 9: 1165-1172 (1989).					
	Kallioniemi et al., Int. J. Cancer, 49: 650-655 (1991).					
	Kelley et al., <i>Biochemistry</i> , 31: 5434-5441 (1992).					
	Kerr et al., Br. J. Cancer, 26: 239-257 (1972).					
	King et al., Science, 229: 974-976 (1985).					
<u> </u>	Kita et al., Biochemical and Biophysical Research Communications, 226: 59-69 (1996).					
	Korman et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2150-2054 (1987).					
	Kraus et al., <i>Proc. Natl. Acad. Sci. USA</i> , 86: 9193-9197 (1989).					
	Lin et al., <i>Gene</i> , 44: 201-209 (1986).					
	Maniatis et al., <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1982).					
	Marchionni et al., <i>Nature</i> , 362: 312-318 (1993).					
	Mendelsohn, Cancer Cells, 7: 359-362 (1989).					
	Muss et al., N. Engl. J. Med, 330: 1260-1266 (1994).					
	Philo et al., <i>J. Biol. Chem.</i> , 269: 27840-27846 (1994).					
· · · · · · · · · · · · · · · · · · ·	Plowman et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90: 1746-1750 (1993).					
	Press et al., in Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part A: Preclinical Aspects pp. 209-221 (1990).					
	Remington's Pharmaceutical Sciences, 18 th ed. A.R. Gennaro, ed. Mack, Easton, PA (1990).					
100	Rilke et al., Int. J. Cancer, 49: 44-49 (1991).					
	Ro et al., Cancer Res., 49: 6941-6944 (1989).					
· · · · · · · · · · · · · · · · · · ·	Savill et al., <i>Nature</i> , 343: 170-173 (1990).					
	Schecter et al., <i>Nature</i> , 312: 515-516 (1984).					

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	6843.0028-02000 Appln. No. 09/994,068	
Applicant	Tsutomu ARAKAWA et al. APR 1 2 2002 (8)	RECEIVED
Filing Date	November 27, 2001 Froup: 1642	APR 1 8 2002
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) [[CH CENTER 1600/290
	Seaver, Gen Eng. News., 14 (14): 10 and 21 (1994).	
	Semba et al., <i>Proc. Natl. Acad. Sci. USA</i> , 82: 6497-6501 (1985).	

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc. TECH CENTER 1600/2
 Seaver, <i>Gen Eng. News.</i> , 14 (14): 10 and 21 (1994).
Semba et al., <i>Proc. Natl. Acad. Sci. USA</i> , 82: 6497-6501 (1985).
Slamon et al., <i>Science</i> , 235: 177-182 (1987).
 Slamon et al., Science, 244: 707-712 (1989).
Srinivas et al., Cancer Immunol. Immunother., 36: 397-402 (1993).
 Stancovaski et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88: 8691-8695 (1991).
Tagliabue et al., Int. J. Cancer, 47: 933-937 (1991).
 Takagi, <i>J. Chromatogr.</i> , 506: 409-446 (1990).
Vitetta and Uhr, Cancer Res., 54: 5301-5309 (1994).
 Wright et al., Cancer Res., 49: 2087-2090 (1989).
Wu et al., <i>J. Clin. Invest.</i> , 95: 1897-1905 (1995).
 Wyllie et al., Int. Rev. Cytol., 68: 251-306 (1980).
 Wyllie et al., <i>Nature</i> , 284: 555-556 (1980).
 Xu et al., Int. J. Cancer., 53: 401-408 (1993).
 Yarden, <i>Proc. Natl. Acad. Sci. USA</i> , 87: 2569-2573 (1990).
Walker et al., Brit. J. Cancer, 60: 426-429 (1989).
 Wen et al., Cell, 64: 559-572 (1992).

Examiner Date Considered		
*Examiner:	*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609 through citation if not in conformance and not considered. Include copy of this form with communication to applicant.	
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce